Anti-tumor immune responses following neoadjuvant immunotherapy with a recombinant adenovirus expressing HSP72 to rodent tumors

Cancer Immunology, Immunotherapy

Volumn 54, Issue 10, 2005, Pages 988-998

  Krewet, James A ^a,b   Ren, Wenhong ^c   Huang, Xue F ^c   Chen, Si Yi ^c   Shah, Maulik R ^a,b,d  

^a SAINT LOUIS UNIVERSITY   (United States)

^b SAINT LOUIS UNIVERSITY CANCER CENTER   (United States)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Gene therapy; Heat shock protein 70; Neoadjuvant therapy

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; HEAT SHOCK PROTEIN 72; IMMUNOMODULATING AGENT; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CELLULAR IMMUNITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; GLIOBLASTOMA; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT; TUMOR; TUMOR GROWTH; TUMOR RESISTANCE; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; DISEASE MODELS, ANIMAL; GENE THERAPY; HEAT-SHOCK PROTEINS; HSP72 HEAT-SHOCK PROTEINS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOADJUVANT THERAPY; NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 23944446306     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0683-4     Document Type: Article

References (44)

1. Quan WD Jr, Palackdharry CS (1997) Common cancers - immunotherapy and multidisciplinary therapy: parts III and IV. Dis Mon 43:745-808
2. Morse MA et al (2002) The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 32:1-6
3. Delman KA et al (2002) Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer. Ann Surg 236:337-342; discussion 342-333
4. Buter J, Pinedo HM (2003) Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored. Curr Oncol Rep 5:171-176
5. Bodar E et al (2002) Immunologic and biologic properties of the primary tumor during prolonged neoadjuvant chemoimmunotherapy. Oncology (Huntingt) 16:32-39
6. Sabel MS et al (2004) Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol 11:147-156
7. Udono H, Srivastava PK (1993) Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med 178:1391-1396
8. Blachere NE, Srivastava PK (1995) Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 6:349-355
9. Li Z, Menoret A, Srivastava P (2002) Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 14:45-51
10. Benihoud K, Yeh P, Perricaudet M (1999) Adenovirus vectors for gene delivery. Curr Opin Biotechnol 10:440-447
11. Chuah MK, Collen D, VandenDriessche T (2003) Biosafety of adenoviral vectors. Curr Gene Ther 3:527-543
12. Huang C et al (2004) Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene. Cancer Sci 95:160-167
13. Okada T et al (2001) AV TK-mediated killing of subcutaneous tumors in situ results in effective immunization against established secondary intracranial tumor deposits. Gene Ther 8:1315-1322
14. Xu D et al (2004) NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 109:499-506
15. Kikuchi T, Moore MA, Crystal RG (2000) Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood 96:91-99
16. Kwon ED et al (1999) Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 96:15074-15079
17. D'Angelica M et al (1999) Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity. Mol Med 5:606-616
18. Townsend SE, Su FW, Atherton JM, Allison JP (1994) Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54:6477-6483
19. Martin-Fontecha A et al (1996) Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur J Immunol 26:1851-1859
20. Kikuchi T, Crystal RG (1999) Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther 10:1375-1387
21. Lee CT et al (1997) Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 8:187-193
22. Brockstedt DG et al (2002) Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy. Mol Ther 6:627-636
23. Park KH et al (2003) Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer. Anticancer Res 23:1559-1564
24. Mazzolini G, Prieto J, Melero I (2003) Gene therapy of cancer with interleukin-12. Curr Pharm Des 9:1981-1991
25. Schagen FH, Ossevoort M, Toes RE, Hoeben RC (2004) Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 50:51-70
26. Clark PR, Menoret A (2001) The inducible Hsp70 as a marker of tumor immunogenicity. Cell Stress Chaperones 6:121-125
27. Massa C et al (2004) Enhanced efficacy of tumor cell vaccines transfected with secretable hsp70. Cancer Res 64:1502-1508
28. Blachere NE et al (1993) Heat shock protein vaccines against cancer. J Immunother 14:352-356
29. Todryk SM, Gough MJ, Pockley AG (2003) Facets of heat shock protein 70 show immunotherapeutic potential. Immunology 110:1-9
30. Ito A, Matsuoka F, Honda H, Kobayashi T (2004) Antitumor effects of combined therapy of recombinant heat shock protein 70 and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma. Cancer Immunol Immunother 53:26-32
31. Todryk S et al (1999) Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163:1398-1408
32. Basu S, Binder RJ, Ramalingam T, Srivastava PK (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303-313
33. Wells AD et al (1998) Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol 10:609-617
34. Ito A et al (2001) Augmentation of MHC class I antigen presentation via heat shock protein expression by hyperthermia. Cancer Immunol Immunother 50:515-522
35. Shah M (1996) Tumor imunity following adenovirus mediated herpes simplex thymidine kinase gene transfer to experimental rat gliomas. Anatomy and Neurobiology Medical College of Virginia, Richmond
36. den Brok MH et al (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64:4024-4029
37. Huang XF et al (2003) A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res 63:7321-7329
38. Mulders P et al (1998) Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. J Immunother 21:170-180
39. Wolf JK et al (2004) A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 94:442-448
40. Ip SM, Huang TG, Yeung WS, Ngan HY (2001) pRb-expressing adenovirus Ad5-Rb attenuates the p53-induced apoptosis in cervical cancer cell lines. Eur J Cancer 37:2475-2483
41. Vassaux G, Martin-Duque P (2004) Use of suicide genes for cancer gene therapy: study of the different approaches. Expert Opin Biol Ther 4:519-530
42. Rosenberg E et al (2002) Radiosensitization of human glioma cells in vitro and in vivo with acyclovir and mutant HSV-TK75 expressed from adenovirus. Int J Radiat Oncol Biol Phys 52:831-836
43. Okubo S et al (2001) Gene transfer of heat-shock protein 70 reduces infarct size in vivo after ischemia/reperfusion in the rabbit heart. Circulation 103:877-881
44. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-74